Talk to Someone: Triple Negative Breast Cancer Named One of the Most Innovative Products of 2018 by PM360
Talk to Someone: Triple Negative Breast Cancer is an online simulation that gives patients the opportunity to navigate through questions about breast cancer and treatment, and get answers from an emotionally responsive virtual triple negative breast cancer survivor named Linda. Patients lead the conversation by selecting questions about breast cancer, chemotherapy, life during treatment, and survivorship to Linda. The goal is to help patients gain the understanding to make the right treatment decision for themselves.
“This app provides a safe and personalized environment for patients to ask questions and approach emotional topics with a judgment-free, empathetic, virtual breast cancer survivor who is always available to talk and never short on time,” says Ron Goldman, Kognito Co-Founder & CEO. “We are excited to extend our use of conversations with virtual humans to offer this new form of patient education.”
Talk to Someone: Triple Negative Breast Cancer was selected as part of PM360’s 7th Annual Innovations Issue published each December. This issue was established to serve as a guide to the year’s most innovative Companies, Startups, Divisions, Products, Services, and Strategies from within the healthcare and life sciences industries. This comprehensive overview of the year’s most innovative achievements in these six categories helps other companies in the industry to find potential partners and offerings that can help them advance healthcare and life sciences.
“Our selections represent the companies, offerings, and strategies that demonstrated what we believe is unique in its ability to impact the industry,” says Anna Stashower, CEO/Publisher of PM360. “We hope others in the industry are able to work with these innovators or use these innovations to better serve patients, physicians, and other healthcare stakeholders.”
PM360 received hundreds of submissions from across the healthcare and life sciences industries. The editorial staff of PM360 evaluated each submission and selected their picks for the most innovative, regardless of category. Ultimately, more than 60 total innovations were featured in the issue. Within the Product category, a total of 18 products were featured.
All of this year’s selections can be found at: www.pm360online.com/pm360-presents-the-2018-innovators.
About Kognito
Kognito is a health simulation company whose evidence-based simulations harness the power of role-play conversations with virtual humans to improve social, emotional, and physical health. Over one million people have engaged with Kognito’s growing portfolio of simulations, used by 300+ leading health, education, government, and nonprofit organizations for professional development and public education. Kognito is the only company with health simulations listed in the National Registry of Evidence-Based Programs and Practices (NREPP). Learn more at kognito.com.
About PM360
PM360 is the premier, must-read magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated healthcare environment.
The journal’s targeted and insightful editorial focuses on issues that directly impact critical decision making, including: Planning and implementation of cutting-edge strategies, trends, the latest technological advances, branding/marketing, advertising/promotion, patient/professional education, sales, market research, PR, and leadership. Additionally, the “360” in the title signifies the span of this critical, how-to info with personal and career insights for an enjoyable and thought-provoking read.
By providing the full circle of enriching content, PM360 is truly an indispensable tool for busy and productive marketing professionals to stay at the top of their game.